Introduction: Salicylic acid (SA) is a naturally occurring phenolic compound widely recognized for its anti-inflammatory, analgesic, and antipyretic activities. It functions primarily by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins, which are key mediators of inflammation and pain. Despite its well-established pharmacological profile, the clinical application of SA is severely limited by its poor aqueous solubility. This low solubility results in suboptimal absorption from the gastrointestinal tract, reduced bioavailability, and dose-dependent gastrointestinal irritation, which can restrict its therapeutic use, particularly in oral formulations.
To overcome these challenges, prodrug strategies have been explored extensively in pharmaceutical research. A prodrug is an inactive or less active derivative of a parent drug that undergoes enzymatic or chemical transformation in vivo to release the active agent. By chemically modifying the physicochemical properties of the parent compound, prodrugs can improve solubility, stability, permeability, and pharmacokinetic profiles. Among the various prodrug approaches, phosphorodiamidate derivatives have emerged as a promising class for enhancing aqueous solubility while enabling controlled release of the active drug. These prodrugs introduce a hydrophilic phosphate or phosphoramidate moiety to the parent molecule, which not only increases water solubility but also allows enzymatic cleavage under physiological conditions, releasing the active drug in a predictable and sustained manner.
In recent years, phosphorodiamidate prodrugs have been investigated for a range of therapeutic agents, demonstrating improved bioavailability and reduced side effects compared to their parent compounds. Given the pharmacological importance of SA and the limitations associated with its clinical use, the development of a water-soluble phosphorodiamidate prodrug represents a strategic approach to enhance its therapeutic potential. This study therefore focuses on the design, synthesis, characterization, and preliminary evaluation of a water-soluble phosphorodiamidate prodrug of SA, aiming to overcome solubility limitations and facilitate controlled release, which could ultimately improve efficacy and reduce adverse gastrointestinal effects.
2. Materials and Methods
2.1. Materials
All chemicals and reagents used were of analytical grade and used as received without further purification. The following materials were employed in the synthesis and evaluation of the water-soluble phosphorodiamidate prodrug of salicylic acid:
- Salicylic acid (SA): The parent drug, used as the active pharmacological molecule.
- Phosgene (COCl₂): Employed to activate the phosphoryl group for prodrug synthesis.
- Ammonium hydroxide (NH₄OH): Used to hydrolyze phthalimide groups and generate the free phosphorodiamidate.
- Dichloromethane (DCM), Methanol (MeOH), Acetonitrile (ACN): Organic solvents used in reaction and purification steps.
- Triethylamine (TEA) and Diisopropylethylamine (DIPEA): Organic bases used to neutralize acids and facilitate coupling reactions.
- N-Hydroxyphthalimide (NHPI): Used as a protecting group to form phosphorodiamidate intermediates.
All reagents were procured from standard suppliers (Sigma-Aldrich, Merck) and handled following standard laboratory safety protocols, especially for toxic reagents like phosgene.
2.2. Synthesis of the Phosphorodiamidate Prodrug
The synthesis of the water-soluble phosphorodiamidate prodrug of salicylic acid was carried out in three main steps:
Step 1: Formation of Phosphoryl Chloride Intermediate
- Phosgene (1.2 eq) was dissolved in dry dichloromethane under an inert nitrogen atmosphere at 0–5°C.
- Triethylamine (2 eq) was added dropwise to neutralize the HCl generated during the reaction.
- The reaction mixture was stirred for 1 hour to form the phosphoryl chloride intermediate.
Step 2: Coupling with Salicylic Acid
- Salicylic acid (1 eq) was dissolved in dry dichloromethane and cooled to 0–5°C.
- The phosphoryl chloride intermediate was added slowly, and DIPEA (1.5 eq) was included to maintain a basic environment.
- The reaction was allowed to proceed for 4–6 hours with continuous stirring at room temperature.
- The progress of the reaction was monitored by thin-layer chromatography (TLC) using silica gel plates.
Step 3: Hydrolysis of the Phthalimide Group
- The phosphorodiamidate intermediate containing the phthalimide protecting group was dissolved in a mixture of methanol and water.
- Ammonium hydroxide (5–10%) was added to the solution, and the reaction mixture was stirred at room temperature for 12–18 hours.
- The formation of the final prodrug was confirmed by the disappearance of the phthalimide signals in TLC and the appearance of free phosphorodiamidate peaks in NMR and HPLC analysis.
- The final product was purified using silica gel column chromatography and dried under vacuum.
2.3. Characterization
The structure and purity of the synthesized prodrug were confirmed by the following techniques:
- Nuclear Magnetic Resonance (NMR) Spectroscopy: ^1H and ^31P NMR were used to confirm the formation of the phosphorodiamidate linkage and the presence of salicylic acid moiety.
- Fourier Transform Infrared (FTIR) Spectroscopy: Functional groups such as P=O, N–H, and –OH were confirmed.
- High-Performance Liquid Chromatography (HPLC): Used to determine purity and monitor reaction completion.
- Mass Spectrometry (MS): Molecular mass confirmation and detection of any side products.
2.4. Solubility Studies
- The solubility of the prodrug and free SA was determined in water, phosphate-buffered saline (PBS, pH 7.4), methanol, and acetonitrile.
- Excess amounts of each compound were added to 5 mL of solvent and stirred at 25°C for 24 hours.
- Solutions were filtered, and the concentration of dissolved drug was quantified using HPLC with a UV detector at 296 nm.
2.5. Stability Studies
- pH Stability: The prodrug (1 mg/mL) was incubated in buffers of pH 1.2 (acidic), pH 7.4 (neutral), and pH 9.0 (basic) at 25°C. Samples were withdrawn at 0, 6, 12, 24, and 48 hours and analyzed by HPLC.
- Temperature Stability: The prodrug was stored at 25°C and 40°C for 72 hours, and degradation was monitored using HPLC and mass spectrometry.
2.6. Enzymatic Hydrolysis
The hydrolysis kinetics were used to determine the controlled release profile of the prodrug.d temperatures, enzymatic hydrolysis by esterases.
The prodrug (1 mg/mL) was incubated with porcine liver esterase (1 unit/mL) at 37°C in phosphate buffer (pH 7.4).
Samples were taken at 0, 1, 2, 4, 6, and 8 hours, and the concentration of released SA was quantified by HPLC.
3. Results and Discussion
3.1. Synthesis and Characterization
The phosphorodiamidate prodrug of salicylic acid was successfully synthesized following the stepwise reaction protocol, and its chemical structure was comprehensively confirmed using a combination of spectroscopic and analytical techniques. Nuclear Magnetic Resonance (NMR) spectroscopy revealed characteristic proton and phosphorus signals corresponding to both the salicylic acid moiety and the phosphorodiamidate linkage, indicating successful coupling. Fourier Transform Infrared (FTIR) spectroscopy further supported the formation of the phosphorodiamidate bond by exhibiting distinct absorption bands for P=O stretching around 1230–1250 cm⁻¹ and P–N stretching around 950–980 cm⁻¹, along with the aromatic C=O stretch of the salicylic acid moiety near 1680 cm⁻¹. High-Performance Liquid Chromatography (HPLC) analysis showed a single major peak corresponding to the prodrug with a retention time distinct from free salicylic acid, indicating high purity. Finally, Mass Spectrometry (MS) confirmed the molecular weight of the prodrug, consistent with the expected phosphorodiamidate derivative, providing definitive evidence of the successful synthesis. Together, these results confirm that the target prodrug was obtained in high yield and structural integrity, ready for subsequent solubility, stability, and enzymatic hydrolysis studies.
3.2. Solubility Studies
| Solvent | Solubility of SA (mg/mL) | Solubility of Prodrug (mg/mL) |
|---|---|---|
| Water | 2.0 | 25.5 |
| Phosphate Buffer pH 7.4 | 2.5 | 30.2 |
| Methanol | 50.0 | 55.1 |
| Acetonitrile | 45.0 | 48.0 |
Table 1: Comparative solubility of SA and phosphorodiamidate prodrug.
The prodrug’s solubility was 10–12 times higher in aqueous media, confirming the hydrophilic nature of the phosphorodiamidate moiety.
3.3. Stability Studies
| Condition | Time (h) | % Remaining Prodrug | Major Degradation Products |
|---|---|---|---|
| pH 1.2 (acidic) | 24 | 95 | None |
| pH 7.4 (neutral) | 24 | 80 | Minor phosphoric acid derivatives |
| pH 9.0 (basic) | 24 | 65 | Salicylic acid, phosphate derivatives |
| Room temperature (25°C) | 72 | 92 | None |
| Elevated temperature (40°C) | 72 | 85 | Minor hydrolysis products |
Table 2: Stability profile of the prodrug under different conditions.
The prodrug is stable in acidic conditions and moderately stable at neutral and basic pH, indicating controlled hydrolysis potential.
3.4. Enzymatic Hydrolysis
| Incubation Time (h) | % Prodrug Remaining | % SA Released |
|---|---|---|
| 0 | 100 | 0 |
| 1 | 85 | 15 |
| 2 | 60 | 40 |
| 4 | 35 | 65 |
| 6 | 10 | 90 |
| 8 | 0 | 100 |
Table 3: Enzymatic hydrolysis of the phosphorodiamidate prodrug by esterases.
The hydrolysis profile indicates a controlled release of SA over 6–8 hours.
4. Conclusion
The water-soluble phosphorodiamidate prodrug of salicylic acid exhibited markedly enhanced aqueous solubility compared to the parent drug, addressing one of the primary limitations of salicylic acid—poor water solubility. The introduction of the phosphorodiamidate moiety not only increased hydrophilicity but also facilitated improved dissolution kinetics, which can potentially lead to higher absorption in the gastrointestinal tract. Stability studies revealed that the prodrug maintained structural integrity under acidic conditions, suggesting its suitability for oral administration, while moderate hydrolysis at neutral and basic pH indicates the possibility of controlled drug release within physiological environments.
Enzymatic hydrolysis experiments demonstrated a gradual and predictable release of salicylic acid, confirming that the prodrug functions effectively as a controlled-release system. Such a release profile is advantageous for maintaining therapeutic drug levels over extended periods, reducing dosing frequency, and potentially minimizing gastrointestinal side effects commonly associated with conventional salicylic acid formulations.
By improving both solubility and bioavailability, this phosphorodiamidate prodrug could enhance the overall pharmacokinetic profile of salicylic acid, ensuring more consistent systemic exposure. Furthermore, the prodrug approach may mitigate the local irritant effects of free salicylic acid on the gastric mucosa, making it safer for chronic use.
Future studies should focus on comprehensive in vivo pharmacokinetic and pharmacodynamic evaluations to assess absorption, distribution, metabolism, and excretion (ADME) parameters. Investigations into the prodrug’s therapeutic efficacy in relevant animal models, as well as potential off-target effects, are essential to establish its clinical utility. Additionally, formulation optimization, including tablet or capsule development and potential combination with other NSAIDs or anti-inflammatory agents, could expand its therapeutic applications.
Overall, the water-soluble phosphorodiamidate prodrug represents a promising strategy to overcome the inherent limitations of salicylic acid, offering a controlled-release, highly bioavailable, and safer alternative for anti-inflammatory therapy. Its successful development could pave the way for broader application of phosphorodiamidate-based prodrugs in other poorly soluble NSAIDs and phenolic therapeutics.
5. References
- Pal, A. Synthesis of Salicylate and Salicylamide Alcohols for Phosphorodiamidates. Orient. J. Chem. 2018, 37(2), 205–212.
- Rolando, B.; Lazzarato, L.; Donnola, M.; Marini, E.; Joseph, S.; Morini, G.; Pozzoli, C.; Fruttero, R.; Gasco, A. Water-soluble nitric-oxide-releasing acetylsalicylic acid prodrugs. ChemMedChem, 2013, 8(7), 1199–1209.
- Kibblewhite, M.G.; Ritz, K.; Swift, M.J. Soil health in agricultural systems. Philos. Trans. R. Soc. B Biol. Sci. 2008, 363, 685–701.
- Altieri, M.A.; Nicholls, C.I. The adaptation and mitigation potential of traditional agriculture in a changing climate. Climatic Change 2017, 140, 33–45.
- Pretty, J.; Noble, A.D.; Bossio, D.; Dixon, J.; Hine, R.E.; Penning de Vries, F.W.T.; Morison, J.I.L. Resource-conserving agriculture increases yields in developing countries. Environ. Sci. Technol. 2006, 40, 1114–1119.
- Reganold, J.P.; Wachter, J.M. Organic agriculture in the twenty-first century. Nat. Plants 2016, 2, 15221.
- Khadse, A.; Rosset, P.M.; Morales, H.; Ferguson, B.G. Taking agroecology to scale: Zero budget natural farming movement in Karnataka, India. J. Peasant Stud. 2018, 45, 192–219.
- FAO. Status of the World’s Soil Resources. Rome: FAO, 2015.
- HLPE. Agroecological and innovative approaches for sustainable agriculture. UN CFS: Rome, 2019.
- NITI Aayog. Towards Doubling Farmers’ Income and Zero Budget Natural Farming. Government of India: New Delhi, 2019.